+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Major Depressive Disorder Drug"

From
Major Depressive Disorder - Epidemiology Forecast - 2032 - Product Thumbnail Image

Major Depressive Disorder - Epidemiology Forecast - 2032

  • Report
  • June 2022
  • 148 Pages
  • Global
From
From
Major Depressive Disorder Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Major Depressive Disorder Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
From
Antidepressants Drugs Market 2025-2029 - Product Thumbnail Image

Antidepressants Drugs Market 2025-2029

  • Report
  • June 2025
  • 209 Pages
  • Global
From
From
From
From
From
From
From
From
Depression Treatment Drugs Companies in China - Product Thumbnail Image

Depression Treatment Drugs Companies in China

  • Report
  • March 2025
  • 55 Pages
  • China
From
Fetzima (levomilnacipran; Allergan) Drug Overview 2019 - Product Thumbnail Image

Fetzima (levomilnacipran; Allergan) Drug Overview 2019

  • Report
  • March 2019
  • 17 Pages
  • Global
Depression Treatment Drugs Markets in China - Product Thumbnail Image

Depression Treatment Drugs Markets in China

  • Report
  • March 2025
  • 211 Pages
  • China
From
Loading Indicator

The Major Depressive Disorder Drug market is a subset of the Mental Disorders Drugs market. It is composed of pharmaceuticals used to treat major depressive disorder, a mental health disorder characterized by persistent feelings of sadness, loss of interest, and fatigue. These drugs are typically prescribed by psychiatrists and other mental health professionals. Commonly prescribed drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). The Major Depressive Disorder Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and Novartis. Show Less Read more